NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- Penghua CSI Animal Husbandry ETF(159867) Rises Slightly by 0.16% Against Market Trend; Institutions: Hog Industry Capacity Reduction Expected to Drive Long-Term Hog Price Center Upward
- Federal Reserve Rate Cut Expectations Decline, ChinaAMC CSI Shanghai-Shenzhen-Hong Kong Gold Industry Commodity ETF (159562) Falls 3.21% in Early Trading
- ChinaAMC CSI Electricity Equipment Theme ETF (159326) Rises Nearly 3% in Early Trading; Global Power Grid Investment to Reach $12 Trillion
- Six Ministries Unite to Drive Orderly Expansion in Solar Module Sector! Csop Huatai-Pinebridge Csi Photovoltaic Industry Etf (03134.HK) Bucks Market Downturn
- GF CSI Military Industry ETF (512680) Rises 1.59%; Institutions: Expectations for Increased Military Trade Share Expected to Continue Strengthening
